Sema4 Holdings Corp.
IPO Year: 2020
Exchange: NASDAQ
Recent Analyst Ratings for Sema4 Holdings Corp.
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/7/2022 | $3.00 → $1.00 | Buy → Neutral | Goldman |
8/16/2022 | $4.00 → $2.00 | Buy → Hold | Jefferies |
6/2/2022 | $3.50 | Buy | Goldman |
11/19/2021 | $12.00 | Buy | Goldman Sachs |
10/8/2021 | $12.00 | Buy | BTIG Research |
9/30/2021 | $13.00 | Outperform | Cowen & Co. |
9/24/2021 | $13.00 | Buy | Jefferies |
Sema4 Holdings Corp. Press Releases
Fastest customizable press release news feed in the world
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland, President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT. A live and archived webcast of the presentation will be available on the "Events" section of the Sema4|GeneDx investor relations website at https://ir.sema4.com/. About Sema4|GeneDx Sema4|GeneDx is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediate potential changes in clinical management. The research evaluates the incidence of mitochondrial disease caused by both nuclear DNA (nDNA) and mtDNA in 966 infants in the NICU who received both rapid exome sequencing and mtDNA sequencing and deletion testing concurrently. Mitochondrial diseases are chronic, genetic disorders that occur when mitochondria fai
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
STAMFORD, Conn., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, supports the new National Society of Genetic Counselors guidelines recommending exome sequencing as a first-tier test, to be prioritized over multi-gene panels for all individuals with unexplained epilepsy, and applauds the American Epilepsy Society for endorsing these guidelines. This is the first evidence-based guideline for genetic testing for individuals with unexplained epilepsy, and the implications are vast, as a significant amount of unexplained epilepsy has a genetic cause1. In many cases, identifying a molecular genetic cause of epilepsy can have implications for treatment and
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
-- Abnormal findings reported in 63% of infants in study, change in health management recommended in 88% of cases ---- Sema4|GeneDx contributes to latest data in the SeqFirst study being presented at the American Society of Human Genetics Annual Meeting -- STAMFORD, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced updated research showing the clear benefits of rapid whole genome sequencing (rWGS) to diagnose critically ill newborns in the neonatal intensive care unit (NICU). The findings come from the recently completed first phase of the SeqFirst study, for which Sema4|GeneDx performed the sequencing, and was conducted in partnershi
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
STAMFORD, Conn., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, has collaborated on research debunking a commonly held belief that exome and genome sequencing deliver more inconclusive results than multi-gene panels. The study demonstrates that using exome or genome sequencing results in a significantly lower rate of variants of uncertain significance (VUS) compared to panel-based testing, underscoring the importance of genomic sequencing for improving diagnoses and health outcomes. It is one of more than a dozen studies Sema4|GeneDX is either presenting, or has participated in, being showcased at the American Society of Human Genetics (ASHG) Annual Meeti
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
Research from 19,000 patients with Autism Spectrum Disorders found approximately 90% had prior negative tests, likely contributing to a longer time to diagnosis Data will be presented at the Child Neurology Society (CNS) Annual Meeting on October 13, 2022 STAMFORD, Conn., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, is presenting research today on autism spectrum disorders (ASD) at the Child Neurology Society (CNS) Annual Meeting. The research underscores the positive outcomes of exome analysis for individuals with ASD, supporting the use of a broader genetic testing approach to reach a faster diagnosis. This study of almost 19,000 individuals is one
Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
STAMFORD, Conn., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it is a partner in the recently launched GUARDIAN study (Genomic Uniform-screening Against Rare Diseases In All Newborns), a collaboration among premier non-profit, academic, government, and industry organizations. GUARDIAN is using whole genome sequencing (WGS) to screen 100,000 newborns for more conditions than those currently included in standard newborn screening. The goals of the study are to drive earlier diagnosis and treatment to improve the health of the babies who participate, generate evidence to support the expansion of newborn screening through genomic sequencing,
Sema4 Holdings Corp. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Sema4 Holdings Corp downgraded by Goldman with a new price target
Goldman downgraded Sema4 Holdings Corp from Buy to Neutral and set a new price target of $1.00 from $3.00 previously
Sema4 Holdings Corp downgraded by Jefferies with a new price target
Jefferies downgraded Sema4 Holdings Corp from Buy to Hold and set a new price target of $2.00 from $4.00 previously
Goldman resumed coverage on Sema4 Holdings Corp with a new price target
Goldman resumed coverage of Sema4 Holdings Corp with a rating of Buy and set a new price target of $3.50
Goldman Sachs initiated coverage on Sema4 Holdings with a new price target
Goldman Sachs initiated coverage of Sema4 Holdings with a rating of Buy and set a new price target of $12.00
BTIG Research initiated coverage on Sema4 Holdings Corp with a new price target
BTIG Research initiated coverage of Sema4 Holdings Corp with a rating of Buy and set a new price target of $12.00
Cowen & Co. initiated coverage on Sema4 Holdings with a new price target
Cowen & Co. initiated coverage of Sema4 Holdings with a rating of Outperform and set a new price target of $13.00
Jefferies initiated coverage on Sema4 Holdings with a new price target
Jefferies initiated coverage of Sema4 Holdings with a rating of Buy and set a new price target of $13.00
Sema4 Holdings Corp. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Ryan Jason bought $161,368 worth of shares (114,742 units at $1.41) (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Pfenniger Richard C Jr bought $14,889 worth of shares (10,000 units at $1.49), increasing direct ownership by 92% to 20,918 units (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Sema4 Holdings Corp. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Saad Kareem sold $625 worth of shares (193 units at $3.24) and converted options into 546 shares, increasing direct ownership by 1% to 24,467 units (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Ryan Jason gifted 73,614 shares, closing all direct ownership in the company (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Saad Kareem sold $271 worth of shares (105 units at $2.58), decreasing direct ownership by 0.43% to 24,114 units (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Saad Kareem converted options into 273 shares, increasing direct ownership by 1% to 24,219 units (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Ryan Jason converted options into 67,780 shares, increasing direct ownership by 1,162% to 73,614 units (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Stueland Katherine converted options into 18,750 shares and sold $25,338 worth of shares (11,734 units at $2.16), increasing direct ownership by 15% to 52,578 units (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Saad Kareem converted options into 5,114 shares and sold $3,671 worth of shares (1,700 units at $2.16), increasing direct ownership by 17% to 23,946 units (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Feeley Kevin converted options into 7,197 shares and sold $6,366 worth of shares (2,948 units at $2.16), increasing direct ownership by 23% to 23,035 units (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Stueland Katherine converted options into 6,546 shares and sold $5,915 worth of shares (3,673 units at $1.61), increasing direct ownership by 7% to 45,562 units (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Saad Kareem sold $1,369 worth of shares (850 units at $1.61) and converted options into 2,841 shares, increasing direct ownership by 11% to 20,532 units (SEC Form 4)
4 - GeneDx Holdings Corp. (0001818331) (Issuer)
Sema4 Holdings Corp. SEC Filings
Sema4 Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - GeneDx Holdings Corp. (0001818331) (Filer)
SEC Form 144 filed by Sema4 Holdings Corp.
144 - GeneDx Holdings Corp. (0001818331) (Subject)
SEC Form 10-Q filed by Sema4 Holdings Corp.
10-Q - GeneDx Holdings Corp. (0001818331) (Filer)
Sema4 Holdings Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
8-K - GeneDx Holdings Corp. (0001818331) (Filer)
SEC Form S-8 filed by Sema4 Holdings Corp.
S-8 - GeneDx Holdings Corp. (0001818331) (Filer)
Sema4 Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - GeneDx Holdings Corp. (0001818331) (Filer)
Sema4 Holdings Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - GeneDx Holdings Corp. (0001818331) (Filer)
Sema4 Holdings Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
8-K - GeneDx Holdings Corp. (0001818331) (Filer)
SEC Form DEFA14A filed by Sema4 Holdings Corp.
DEFA14A - GeneDx Holdings Corp. (0001818331) (Filer)
Sema4 Holdings Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - GeneDx Holdings Corp. (0001818331) (Filer)
Sema4 Holdings Corp. Leadership Updates
Live Leadership Updates
Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer
STAMFORD, Conn., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced that the Company has appointed Kevin Feeley as Chief Financial Officer (CFO), completing its previously announced search for the CFO position. Mr. Feeley, who has held the roles of Senior Vice President of Operations and Head of GeneDx at Sema4 since May 2022, will also continue to lead all key operational aspects of the Company. "As we shared during our recent earnings call, our new management team is committed to profitable growth, efficiency, and scale. Kevin's broad industry experience and successful financial leadership of GeneDx during an accelerated phase of commercial
Sema4 Announces Chief Financial Officer Transition Plan
Appoints Richard Miao, Sema4's Deputy Chief Financial Officer, as interim Chief Financial Officer Reiterates the financial guidance provided on May 12, 2022 STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced its Chief Financial Officer (CFO), Isaac Ro, will be leaving the company on August 9, 2022. Effective immediately, Richard Miao, Sema4's Deputy CFO, will serve as interim CFO while the company conducts a search for a permanent CFO. Mr. Ro will provide consulting services to Sema4 for six months to facilitate a smooth transition of responsibilities. "We are extremely thankful fo
Sema4 Holdings Corp. Financials
Live finance-specific insights
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast
Sema4 Announces Continued Restructuring, Business Highlights, and Reports Second Quarter 2022 Financial Results
New management team implements significant restructuring to focus on profitable growth, efficiency, and scale 19% pro forma1 volume growth vs. 2Q 2021 Sema4 to host a conference call today at 4:30 p.m. ET STAMFORD, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced a series of corporate realignments, business highlights, and financial results for the second quarter ended June 30, 2022. "We saw strong volume growth in both our reproductive health and recently acquired pediatrics and rare disease businesses, which delivered on record volumes. The underlying performance of the legacy GeneDx busi
Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
STAMFORD, Conn., July 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the second quarter of 2022 after the market close on Monday, August 15, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Richard Miao, Interim Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the
Sema4 Reports First Quarter 2022 Financial Results and Business Highlights
Total revenue of $53.9 million 1,300 basis points of sequential adjusted gross margin improvement Reaffirming full year 2022 pro forma revenue target New operating model and focus on efficiencies to reduce 2022 cash burn by an estimated $50 million, extending cash runway into 2024 Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., May 12, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the first quarter ended March 31, 2022 and provided an update on key strategic and operational initiatives. "I am very pleased by our start to the yea
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx, joins Sema4 as CEO and will serve on Board of Directors Eric Schadt, founder and former CEO of Sema4, to serve as President and Chief Research & Development Officer and to continue to serve on Board of Directors Sema4 closes $200 million private placement from leading growth and life sciences investors, including Pfizer STAMFORD, Conn., May 02, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it has completed
Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the first quarter of 2022 after the market close on Thursday, May 12, 2022. On the same day, Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4, and Isaac Ro, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET. Conference Call Details The conference call will begin at 4:30 p.m. ET on Thursday, May 12, 2022. Interested parties may access the live teleconference by dialing (844) 631-4065 for domestic callers or (929
Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue (excluding COVID-19 tests) compared to the same period last year Reiterating full year 2022 total revenue guidance of $215-225 million Sema4 to host conference call today at 4:30 p.m. ET STAMFORD, Conn., March 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), an AI-driven genomic and clinical data intelligence platform company, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on key strategic and ope
Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for the fourth quarter and full year 2021 after the market close on Monday, March 14, 2022. On the same day, Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4, and Isaac Ro, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 4:30 p.m. ET. Additionally, Company management will participate in two virtual investor conferences in March. Fourth Quarter and Full Year 2021 Conference Call Details The conference call will begin at 4:30 p.
Sema4 Holdings Corp. Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G filed by Sema4 Holdings Corp.
SC 13G - GeneDx Holdings Corp. (0001818331) (Subject)
SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SEC Form SC 13G/A filed by Sema4 Holdings Corp. (Amendment)
SC 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)
SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)
SEC Form SC 13G filed by Sema4 Holdings Corp.
SC 13G - GeneDx Holdings Corp. (0001818331) (Subject)
SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)
SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)